Here's what we'll cover
Here's what we'll cover
If you've been waiting for Mounjaro to become affordable in Australia, this news stings. The federal government's Pharmaceutical Benefits Scheme — the program that subsidizes medications for millions of Australians — will not be listing tirzepatide (Mounjaro) after talks with its manufacturer, Eli Lilly, collapsed.
The phrase being used by insiders? "The system is broken."
For people managing obesity or type 2 diabetes who were counting on subsidized access, this standoff between a government health body and a pharmaceutical giant has very human consequences.
What the PBS Is and Why It Matters
The Pharmaceutical Benefits Scheme is Australia's government-run drug subsidy program. When a medication gets listed on the PBS, eligible patients can access it for a fraction of its market price — often as little as $7–$30 per prescription.
Without that listing, patients pay the full out-of-pocket cost. For a monthly injectable medication like Mounjaro, that can run into hundreds of dollars per month — a price point that's simply out of reach for many people who need it most.
PBS listing isn't automatic. Drug makers submit pricing proposals, and the government's independent advisory body — the Pharmaceutical Benefits Advisory Committee (PBAC) — assesses whether the cost is justified by the clinical benefit. If a manufacturer won't agree to the government's price, the drug simply doesn't get listed.
Why Negotiations Broke Down
The core issue is a pricing standoff. Eli Lilly, Mounjaro's US-based manufacturer, and Australian health authorities could not agree on what the government would pay per dose.
This kind of impasse isn't unique to Australia. Across the UK, Canada, and Europe, governments are wrestling with the same challenge: GLP-1 medications deliver measurable clinical results, but their list prices strain national health budgets at scale. When millions of people are potentially eligible for a drug, even a small per-dose cost adds up to an enormous public expenditure.
From a pharmaceutical company's perspective, pricing reflects years of research investment and the global market value of the drug. From a government's perspective, sustainability of the entire health system has to come first.
Neither side is entirely wrong — but patients are caught in the middle.
What This Means If You're in Australia Right Now
If you're an Australian currently on tirzepatide or hoping to start it, this decision has immediate implications.
You can still access Mounjaro privately. The medication is approved by Australia's Therapeutic Goods Administration (TGA) for type 2 diabetes management. That means a doctor can prescribe it — you'll just pay the full private price, which is significantly higher without PBS subsidy.
Cost will remain a major barrier. Without subsidization, Mounjaro will likely remain out of reach for lower-income patients, even those with the most medical need. This raises serious equity concerns that go beyond any one medication.
The situation may not be permanent. Pricing negotiations between governments and pharmaceutical companies can restart. Ozempic (semaglutide) faced its own access challenges in various markets before becoming more widely available. Advocacy, political pressure, and market changes can all shift outcomes.
Talk to your doctor or an endocrinologist about what alternatives are currently subsidized and appropriate for your specific situation.
The Broader Problem This Exposes
The "broken system" framing isn't just frustration — it reflects a genuine structural tension in how modern healthcare systems handle high-cost, high-demand medications.
GLP-1 receptor agonists like tirzepatide and semaglutide represent a genuinely new class of treatment. The clinical evidence for weight management and metabolic health is strong. But health systems built around older cost frameworks weren't designed for medications that are simultaneously effective, chronic-use, and expensive at population scale.
Australia isn't alone. In the United States, GLP-1 medications are largely not covered by Medicare for obesity treatment, though this may change. In the UK, NHS access to tirzepatide is being rolled out gradually through specialist pathways. Globally, access equity for these medications remains a serious unresolved issue.
The Australia standoff is a visible symptom of a much bigger, systemic challenge.
What Patients Can Do
If you're affected by this decision — or worried about access to GLP-1 therapy in general — here are some practical steps worth considering.
Talk to your doctor first. Your physician can walk you through what's currently subsidized and what clinical criteria you may meet. In Australia, semaglutide (Ozempic) does have PBS listing for type 2 diabetes under specific conditions.
Ask about patient support programs. Pharmaceutical companies sometimes offer access programs or compassionate use pathways for patients who cannot afford full price. It's worth asking your prescriber or contacting Eli Lilly directly.
Stay informed. Situations like this can change. PBS listing decisions are reviewed, political priorities shift, and new negotiations can begin. Following credible health news sources will help you stay current.
Consider advocacy. Patient groups and chronic disease organizations do influence policy. If affordable access to effective medication matters to you, connecting with diabetes or obesity advocacy organizations in Australia can amplify the collective voice.
Bottom Line
The collapse of Mounjaro's PBS listing in Australia is a setback for patients who need tirzepatide and can't afford it at full private cost. It reflects a larger, unresolved tension between pharmaceutical pricing and public health system sustainability — a tension playing out in countries around the world.
This doesn't mean access is impossible, but it does mean patients need to advocate for themselves and work closely with their healthcare providers to find a path forward.
If you're considering GLP-1 therapy or navigating access challenges, always start with a conversation with a licensed physician who understands your full medical picture.
GLP-1.com does not provide medical advice. Always consult a qualified healthcare professional before starting, stopping, or adjusting any medication.
No waiting list. No insurance needed.
Frequently Asked Questions
Will Mounjaro ever be listed on the PBS in Australia?
The current negotiations between Eli Lilly and Australian health authorities have collapsed, but that does not mean the situation is permanent. PBS listing decisions can be reviewed, and new negotiations can restart if pricing terms change or if political pressure increases. Semaglutide (Ozempic) faced similar access hurdles in various markets before achieving broader availability. Patients and advocacy groups continuing to push for access can influence future negotiations.
Can Australian patients still access Mounjaro without a PBS listing?
Yes. Mounjaro is approved by Australia's Therapeutic Goods Administration (TGA) for type 2 diabetes management, which means a licensed physician can prescribe it privately. The significant difference is cost: without PBS subsidization, patients pay the full private price rather than the $7 to $30 subsidized rate, making it financially out of reach for many people who need it most.
What GLP-1 medications are currently subsidized on the PBS?
Semaglutide (Ozempic) has PBS listing for type 2 diabetes management under specific clinical criteria. Patients who meet those criteria may be able to access subsidized semaglutide through a licensed prescriber. Wegovy, the higher-dose weight-management formulation of semaglutide, does not have PBS listing as of mid-2026. Talk to your doctor or endocrinologist about which subsidized options may be appropriate for your situation.
Why did the Mounjaro PBS negotiations fail?
The core issue was a pricing disagreement between Eli Lilly and Australia's Pharmaceutical Benefits Advisory Committee (PBAC). Eli Lilly sought a price per dose that the government considered unsustainable at population scale, while the PBAC's mandate requires assessing whether clinical benefit justifies cost to the broader health system. Neither party reached an agreement acceptable to both sides. This type of standoff is not unique to Australia and reflects a global tension between pharmaceutical pricing and public health budgets.
Does the Australian PBS listing failure affect New Zealand or other countries?
Each country manages its own drug subsidy and reimbursement decisions independently. The Australian outcome does not directly determine access in New Zealand, the UK, Canada, or elsewhere, though it adds to the broader global conversation about GLP-1 affordability at the population level. The UK's NHS has been rolling out tirzepatide access through specialist pathways, and other countries are at various stages of their own coverage negotiations.
What should Australian patients do if they cannot afford Mounjaro privately?
Start by speaking with your doctor about what is currently PBS-listed and clinically appropriate for your situation, including whether semaglutide under its existing PBS criteria might suit your needs. Ask your prescriber or contact Eli Lilly directly about any patient support or compassionate access programs. Consider connecting with diabetes or obesity advocacy organizations in Australia, since patient advocacy groups do influence policy outcomes and collective voices can accelerate future PBS listing negotiations.